The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to here...

Abstract The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.

The present invention relates for the production of high level expression of recombinant toxin protein CRM 197, production in bacterial hosts. In particular, the present invention relates to recombinant microorganisms, are disclosed that have been engineered to express a CRM 197 alone or in combination with recombin...

Abstract of the Invention The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the...

A new manufacturing process for preparing pure capsular polysachharide using aluminum phosphate with alcohol for the purification of capsular polysaccharides of Haemophilus influenza - b, Neisseria meningitis such as serotypes A,C,Y,W-135 and other similar related capsular polysaccharides produced form both gram neg...

The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRM197 whe...

The present invention relates to a soft-gelatin capsule formulation of antitussive agents. More particularly, the present invention relates to soft-gelatin capsule formulation comprising Noscapine or its pharmaceutically acceptable salts alone or in combination with one or more therapeutically active agents. ...

Abstract of the invention The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F of S. pneumoniae activated with CDAP and con...

The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also ...

The present invention relates to multivalent pneumococcal polysaccharide-protein conjugates vaccine composition comprising pneumococcal capsular polysaccharide of one or more Streptococcus pneumoniae serotypes conjugated to one or more carrier proteins.

The present invention relates to multivalent pneumococcal polysaccharide-protein conjugates vaccine composition comprising pneumococcal capsular polysaccharide of one or more Streptococcus pneumoniae serotypes conjugated to one or more carrier proteins.

The present invention provides an improved process for the preparation of Dalteparin sodium. The process is simple, commercially viable and industrially advantageous.

PROCESS FOR THE PREPARATION OF LOW MOLECULAR WEIGHT HEPARIN The  present  invention  provides  an  improved  process  for  the  preparation  of Enoxaparin sodium. The process is simple, commercially viable and industrially advantageous.

An industrially scalable method for the preparation of carrier proteins selected from tetanus toxoid (TT), diphtheria toxoid (DT), Cross Reactive Material 197 (CRM197), Haemophilus influenzae protein D, Neisseria outer membrane protein, Pertussis toxin (PT), Pertactin (PRN) and filamentous hemagglutinin (FHA) and...

The present invention provides an improved method for the production of CRM197 with high yield using engineered Corynebacterium diphtheria strain having increased copy number of CRM197 gene, wherein the method comprises growing the strain in a media free of animal derived components with one or more amino acids. ...

The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alco...

The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.

The present invention provides an alcohol free purification process of capsular polysaccharides. The present invention is an improvement over the existing processes which are tedious and complex multi-step processes. The purification process of the present invention does not involve use of alcohol, chromatographic m...

The present invention relates to multivalent pneumococcal polysaccharide-protein conjugates vaccine composition comprising pneumococcal capsular polysaccharide of one or more Streptococcus pneumoniae serotypes conjugated to one or more carrier proteins.

The present invention provides inactivated poliomyelitis vaccine compositions comprising at least one inactivated poliovirus S19 strain for prevention of poliomyelitis. The present invention provides safe, stable and effective vaccine formulations which can be manufactured at low containment level leading to large s...

The present invention provides a method for purification of Streptococcus pneumoniae Type 3 capsular polysaccharide from fermentation broth comprising protein and complex impurities. The method provides for purification of capsular polysaccharide of Streptococcus pneumonia serotype 3 at a lower temperature range of ...

The present invention provides a colorimetric based method for quantifying carbohydrates in a given aqueous sample. The method provided by the invention uses 2-Phenoxyethanol as a novel reagent for quantifying carbohydrates in a given sample. The present invention is a rapid, sensitive, simple and direct method for ...

The invention relates to an N-terminal extension sequences which are employed to enhance the expression of recombinant therapeutic peptides. The invention also relates to a process for the 5 high-level expression of recombinant therapeutic peptides using the said N-terminal extension sequence. The invention also pro...

PLEASE SEE THE ATTACHED SPECIFICATION

PLEASE SEE THE ATTACHMENTS.

PLEASE SEE THE ATTACHMENTS.

The present invention relates to an immunogenic composition comprising Vi capsular polysaccharide protein conjugate. More particularly, the present invention provides an immunogenic composition comprising fragmented Vi capsular polysaccharide having an average molecular weight between 100-200 KD conjugated to a carr...

The present invention pertains to a multivalent vaccine formulation comprising at least one inactivated poliovirus (IPV) S19 strain selected from S19 Type 1, S19 Type 2 and S19 Type 3 and at least one antigen selected from Diphtheria toxoid (DT), Tetanus toxoid (TT), whole-cell Bordetella pertussis (wP), acellular P...

PLEASE SEE THE ATTACHED SPECIFICATION

The present invention relates to field of protein expression. It provides expression constructs and methods for increased expression of recombinant proteins. More particularly, it provides constructs and methods for enhanced expression of Lira-peptide in a recombinant host cell.

The present invention broadly relates to the improved method for purification of capsular polysaccharides. Particularly, the present invention relates to the method of purification of capsular polysaccharides from Streptococcus pneumoniae and other similar related capsular polysaccharides produced from both gram-neg...

The present disclosure relates to a process for preparing a stable floccule of paliperidone ester injectable suspension. The process comprises wet milling a premix slurry comprising paliperidone ester to obtain a milled suspension; and subjecting the milled suspension to heat treatment to produce a stable floccule o...

“EXPRESSION CASSETTES FOR PROTEIN EXPRESSION, METHOD(S) AND APPLICATION(S) THEREOF” ABSTRACT The present disclosure relates to expression cassettes that enhance protein secretion. The expression cassettes are composed of a specific combination of polynucleotides encoding expression enhancers and signal peptide...

The present disclosure relates to compositions and methods for stabilizing immunogenic compositions. Particularly, the present disclosure provides an easy to prepare and economical stabilizer composition comprising components selected from a group comprising sugar(s), amino 10 acid(s), protein(s) or peptide(s), m...

The present invention relates to a method for covalent coupling of polysaccharides to proteins for the preparation of Pneumococcal Conjugate Vaccines (monovalent) using low quantities/ratios of 1-Cyano 4-Dimethyl Amino Pyridinium tetrafluoroborate (CDAP) thereby preventing the destruction of immunogenic epitopes and...